Innovative Oncology Focus Trilo Therapeutics specializes in advanced antibody-drug conjugates and peptide-drug conjugates targeting cancer, presenting opportunities to collaborate with pharmaceutical and biotech companies seeking cutting-edge oncology solutions.

Growing Funding Support With a recent funding of 1.7 million dollars, Trilo is positioned for continued research and development, making it a promising partner for investors and organizations interested in emerging biotech innovations.

Small but Agile Team Operating with a lean team of 2 to 10 employees, Trilo offers flexibility for strategic partnerships focused on research collaborations, licensing agreements, or joint development projects.

Sustainable Technology Use Utilizing web technologies like WordPress and Microsoft 365, Trilo demonstrates digital savviness that could facilitate remote collaboration, data sharing, and communication with industry partners.

Market Opportunities Potential sales opportunities exist with large pharma companies like Roche, Johnson & Johnson, and Merck, who are continually investing in innovative oncology therapeutics, aligning with Trilo's focus areas.